Search results for "Lymphocyte"

showing 10 items of 2280 documents

Immunological characteristics of non-intensive care hospitalized COVID-19 patients: A preliminary report

2021

The outbreak of coronavirus disease 2019 (COVID-19) is posing a threat to global health. This disease has different clinical manifestations and different outcomes. The immune response to the novel 2019 coronavirus is complex and involves both innate and adaptive immunity. In this context, cell-mediated immunity plays a vital role in effective immunity against SARS-CoV-2. Significant differences have been observed when comparing severe and non-severe patients. Since these immunological characteristics have not been fully elucidated, we aimed to use cluster analysis to investigate the immune cell patterns in patients with COVID-19 who required hospitalization but not intensive care. We identi…

Lymphocytelcsh:MedicineArticleimmune system deficiency03 medical and health sciences0302 clinical medicineImmune systemImmunityIntensive caremedicineCytotoxic T cell030304 developmental biology0303 health sciencesbiologybusiness.industrySARS-CoV-2lcsh:RGeneral MedicineAcquired immune systemmedicine.anatomical_structureGranzymemultiparametric flow cytometryImmunologybiology.proteinbusinessCluster analysis Immune system deficiencyMultiparametric flow cytometry SARS-CoV-2CD8030215 immunologycluster analysis
researchProduct

Modulation of Contact Sensitivity Responses by Bacterial Superantigen

1995

Superantigens are potent modulators of the immune system, especially T cells. Therefore, we determined the influence of superantigens on the T-cell-mediated immune response, contact sensitivity. We chose the combination of staphylococcal enterotoxin B (SEB) as superantigen and 2,4-dinitrofluorbenzene (DNFB) as the contact sensitizer, because in BALB/c mice SEB reacts almost exclusively with V beta 8+ T cells, and these cells are capable of transferring contact sensitivity to DNFB from sensitized donors to naive syngeneic recipients. Pretreatment with a single intradermal injection of 50 ng SEB 24 h before DNFB exposure at the same site on the lower abdomen enhanced the induction of contact …

Lymphoid Tissue24-dinitrofluorbenzeneReceptors Antigen T-Cell alpha-betaT-LymphocytesDown-Regulationchemical and pharmacologic phenomenaDermatologyEnterotoxinDermatitis Contactcontact sensitivityBacterial superantigenBiochemistrysuperantigenProinflammatory cytokineEnterotoxinsInterferon-gammaMiceImmune systemmedicineSuperantigenAnimalsIntradermal injectionMolecular BiologySensitizationSkinAntigens BacterialMice Inbred BALB CSuperantigensbusiness.industryhemic and immune systemsCell BiologyContact sensitivitybiological factorsStaphylococcal enterotoxin Bmedicine.anatomical_structureImmunologyDinitrofluorobenzeneFemaleImmunizationbusinessJournal of Investigative Dermatology
researchProduct

Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting c…

2000

Abstract Background: Hu-PBL-SCID mice generated by the transfer of PBMCs from atopic individuals may provide a physiologic in vivo model for investigating human responses to allergens and potential approaches toward immunotherapy. Objective: This study was undertaken to investigate the functional activity and cytokine profile of human allergen-reactive T lymphocytes isolated from hu-PBL-SCID mice. Methods: PBMCs from allergic individuals were coinjected with allergen into SCID mice. Human lymphocyte migration and phenotype were established by reverse transcription–PCR and immunohistochemistry, IgE levels in sera were determined, and the frequency of allergen-reactive cytokine-producing T ly…

Lymphoid Tissuemedicine.medical_treatmentT-LymphocytesImmunologyAntigen-Presenting CellsMice SCIDBiologyImmunoglobulin EEpitopesMiceImmune systemTh2 CellsCell MovementmedicineImmunology and AllergyAnimalsHumansInterferon gammaRNA MessengerAntigen-presenting cellInterleukin 5Cells CulturedT lymphocyteImmunotherapyAllergensImmunoglobulin ECytokineImmunologyAntibody Formationbiology.proteinCytokinesPeritoneumSpleenmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.

2016

The hepatitis C virus (HCV) infected patients are prone to develop bone marrow or various tissue infiltrates with monoclonal B cells, monoclonal B lymphocytosis or different types of B cell non-Hodgkin's lymphoma (BCNHL), of which the most common are splenic marginal zone BCNHL, diffuse large BCNHL and follicular lymphoma. The association between chronic HCV infection and non Hodgkin's lymphoma has been observed especially in areas with high prevalence of this viral infection. Outside the limitations of some studies that have been conducted, there are also geographic, environmental, and genetic factors that contribute to the epidemiological differences. Various microenvironmental signals, s…

Lymphoma B-CellFollicular lymphomaAntineoplastic AgentsVirus ReplicationAntiviral Agents03 medical and health sciences0302 clinical medicinemedicineHumansLymphoma FollicularB cellCell ProliferationHepatitisB-Lymphocytesbusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsGastroenterologyHematopoietic Stem Cell TransplantationMinireviewsGeneral MedicineHepatitis CLymphoma B-Cell Marginal ZoneHepatitis BHepatitis C Chronicmedicine.diseaseLymphomaNon-Hodgkin's lymphomaLiver Transplantationmedicine.anatomical_structure030220 oncology & carcinogenesisImmunology030211 gastroenterology & hepatologyRituximabLymphoma Large B-Cell DiffuseHepatitis C AntigensbusinessRituximabmedicine.drugWorld journal of gastroenterology
researchProduct

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

2008

Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non–Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell–engag…

Lymphoma B-CellT-Lymphocytesmedicine.medical_treatmentT cellAntineoplastic AgentsLymphoma Mantle-CellImmunophenotypingImmunophenotypingRecurrenceAntibodies BispecificmedicineHumansCytotoxic T cellLymphocyte CountLymphoma FollicularB-LymphocytesMultidisciplinarybusiness.industryCancerImmunotherapymedicine.diseaseLeukemia Lymphocytic Chronic B-CellLeukemiamedicine.anatomical_structureImmunologyCancer researchBlinatumomabBone marrowbusinessImmunologic MemoryT-Lymphocytes Cytotoxicmedicine.drugScience
researchProduct

mTORC1 activation in B cells confers impairment of marginal zone microarchitecture by exaggerating cathepsin activity

2018

Mammalian target of rapamycin complex 1 (mTORC1) is a key regulator of cell metabolism and lymphocyte proliferation. It is inhibited by the tuberous sclerosis complex (TSC), a heterodimer of TSC1 and TSC2. Deletion of either gene results in robust activation of mTORC1. Mature B cells reside in the spleen at two major anatomical locations, the marginal zone (MZ) and follicles. The MZ constitutes the first line of humoral response against blood‐borne pathogens and undergoes atrophy in chronic inflammation. In previous work, we showed that mice deleted for TSC1 in their B cells (TSC1(BKO)) have almost no MZ B cells, whereas follicular B cells are minimally affected. To explore potential underl…

Lymphotoxin-beta0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesImmunologyMice TransgenicSpleenCHO CellsmTORC1Lymphocyte proliferationMechanistic Target of Rapamycin Complex 1Tuberous Sclerosis Complex 1 ProteinCathepsin BCell LineMice03 medical and health sciencesCricetulus0302 clinical medicineLymphotoxin beta ReceptorTuberous Sclerosis Complex 2 ProteinmedicineAnimalsImmunology and AllergyReceptorLymphotoxin-alphaSirolimusCathepsinB-LymphocytesChemistryOriginal ArticlesMarginal zoneCathepsinsCell biology030104 developmental biologymedicine.anatomical_structureLymphotoxinSpleen030215 immunologyImmunology
researchProduct

Eicosapentaenoic acid and docosahexaenoic acid modulate MAP kinase (ERK1/ERK2) signaling in human T cells

2001

This study was conducted on human Jurkat T cell lines to elucidate the role of EPA and DHA, n-3 PUFA, in the modulation of two mitogen-activated protein (MAP) kinases, that is, extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2). The n-3 PUFA alone failed to induce phosphorylation of ERK1/ERK2. We stimulated the MAP kinase pathway with anti-CD3 antibodies and phorbol 12-myristate 13-acetate (PMA), which act upstream of the MAP kinase (MAPK)/ERK kinase (MEK) as U0126, an MEK inhibitor, abolished the actions of these two agents on MAP kinase activation. EPA and DHA diminished the PMA- and anti-CD3-induced phosphorylation of ERK1/ERK2 in Jurkat T cells. In the present study, PMA act…

MAPK/ERK pathwayCD3 ComplexDocosahexaenoic AcidsMAP Kinase Signaling SystemT-LymphocytesQD415-436Arachidonic AcidsLymphocyte Activationfatty acidsBiochemistryJurkat cellsAntibodiesJurkat Cellschemistry.chemical_compoundEndocrinologyHumansPhosphorylationProtein Kinase CProtein kinase CMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3MAP kinase kinase kinasebiologyKinaseIonomycinfood and beveragesCell BiologyCell biologyEnzyme ActivationBiochemistrychemistryMitogen-activated protein kinasebiology.proteinPhorbolTetradecanoylphorbol AcetatePhosphorylationlipids (amino acids peptides and proteins)T cell receptorMitogen-Activated Protein KinasesJournal of Lipid Research
researchProduct

Interferon-α Suppresses cAMP to Disarm Human Regulatory T Cells

2013

Abstract IFN-α is an antineoplastic agent in the treatment of several solid and hematologic malignancies that exerts strong immune- and autoimmune-stimulating activity. However, the mechanisms of immune activation by IFN-α remain incompletely understood, particularly with regard to CD4+CD25highFoxp+ regulatory T cells (Treg). Here, we show that IFN-α deactivates the suppressive function of human Treg by downregulating their intracellular cAMP level. IFN-α–mediated Treg inactivation increased CD4+ effector T-cell activation and natural killer cell tumor cytotoxicity. Mechanistically, repression of cAMP in Treg was caused by IFN-α–induced MAP–ERK kinase (MEK)/extracellular signal-regulated ki…

MAPK/ERK pathwayCancer Researchmedicine.medical_treatmentGraft vs Host DiseaseAutoimmunitychemical and pharmacologic phenomenaBiologyLymphocyte ActivationT-Lymphocytes RegulatoryNatural killer cellMiceImmune systemDownregulation and upregulationT-Lymphocyte SubsetsCyclic AMPmedicineAnimalsHumansIL-2 receptorPhosphorylationExtracellular Signal-Regulated MAP KinasesCells CulturedMitogen-Activated Protein Kinase KinasesInterleukin-2 Receptor alpha SubunitInterferon-alphaFOXP3hemic and immune systemsDNA-Binding ProteinsKiller Cells NaturalSTAT Transcription Factorsmedicine.anatomical_structureCytokineOncologyHumanized mouseImmunologyCancer researchCancer Research
researchProduct

Cilomilast counteracts the effects of cigarette smoke in airway epithelial cells.

2010

Abstract Cigarette smoke extracts (CSE) alter TLR4 expression and activation in bronchial epithelial cells. Cilomilast, a phosphodiesterase-4 inhibitor, inhibits cigarette smoke-induced neutrophilia. This study was aimed to explore whether cilomilast, in a human bronchial epithelial cell line (16-HBE), counteracted CSE effects. In particular, TLR4 expression, IP-10 and IL-8 release, lymphocyte and neutrophil chemotactic activity and ERK and IkBa phosphorylation in CSE and LPS-stimulated 16-HBE were assessed. CSE increased TLR4 expression, reduced IP-10 release and lymphocyte chemotactic activity and increased IL-8 release and neutrophil chemotactic activity. Cilomilast reduced TLR4 expressi…

MAPK/ERK pathwayCyclohexanecarboxylic AcidsLymphocyteImmunologyCyclohexanecarboxylic AcidRespiratory MucosaBiologyCell LineSmokeparasitic diseasesNitrilesmedicineHumansLymphocytesCOPDChemotaxisCilomilastInterleukin-8ChemotaxiChemotaxisTobacco Use Disordermedicine.diseaseNeutrophiliaChemokine CXCL10Toll-Like Receptor 4medicine.anatomical_structureGene Expression RegulationPhosphodiesterase 4 InhibitorImmunologyTLR4PhosphorylationLymphocytePhosphodiesterase 4 Inhibitorsmedicine.symptomNitrileHumanmedicine.drugSignal TransductionCellular immunology
researchProduct

An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression.

2007

Abstract Adoptive cellular immunotherapy inducing a graft-versus-tumor (GVT) effect is the therapeutic mainstay of allogeneic hematopoietic stem cell transplantation (ASCT) for high-risk leukemias. Autologous immunotherapies using vaccines or adoptive transfer of ex vivo–manipulated lymphocytes are clinically explored in patients with various cancer entities. Main reason for failure of ASCT and cancer immunotherapy is progression of the underlying malignancy, which is more prevalent in patients with advanced disease. Elucidating the molecular mechanisms contributing to immune escape will help to develop strategies for the improvement of immunologic cancer treatment. To this end, we have und…

MAPK/ERK pathwayCytotoxicity ImmunologicAdoptive cell transferTranscription GeneticMAP Kinase Signaling Systemmedicine.medical_treatmentImmunologyMolecular Sequence DataApoptosisBiologyBiochemistryMiceImmune systemCancer immunotherapyNeoplasmsmedicineCytotoxic T cellAnimalsHumansLymphocytescdc42 GTP-Binding ProteinCells CulturedBase SequenceCancerCell BiologyHematologymedicine.diseaseGene Expression Regulation NeoplasticMice Inbred C57BLCdc42 GTP-Binding ProteinProto-Oncogene Proteins c-bcl-2ImmunologyCancer cellCancer researchDisease SusceptibilityNeoplasm TransplantationBlood
researchProduct